Stereotactic Body Radiation Therapy for Low- to Intermediate-risk Prostate Adenocarcinoma.
10.3346/jkms.2015.30.6.710
- Author:
Bae Kwon JEONG
1
;
Hojin JEONG
;
In Bong HA
;
Hoon Sik CHOI
;
Sung Chul KAM
;
Jeong Seok HWA
;
Jae Seog HYUN
;
Ky Hyun CHUNG
;
See Min CHOI
;
Ki Mun KANG
Author Information
1. Department of Radiation Oncology, Gyeongsang National University School of Medicine, Jinju, Korea. jsk92@gnu.ac.kr
- Publication Type:Original Article ; Clinical Trial
- Keywords:
Prostate Neoplasms;
Stereotactic Body Radiation Therapy;
Cyberknife Radiosurgery;
Prostate-Specific Antigen
- MeSH:
Adenocarcinoma/*diagnosis/*surgery;
Aged;
Aged, 80 and over;
Humans;
Male;
Middle Aged;
Prostatic Neoplasms/*diagnosis/*surgery;
Radiosurgery/*methods;
Radiotherapy Dosage;
Radiotherapy Planning, Computer-Assisted;
Radiotherapy, Image-Guided/*methods;
Risk Assessment;
Treatment Outcome
- From:Journal of Korean Medical Science
2015;30(6):710-715
- CountryRepublic of Korea
- Language:English
-
Abstract:
The aim of the present study was to evaluate the efficacy and toxicity of stereotactic body radiation therapy (SBRT) for low- to intermediate-risk prostate adenocarcinoma. Thirty-nine patients were retrospectively reviewed. The SBRT was delivered using the CyberKnife with the fiducial tracking method combined with In-tempo imaging. The gross target volume, which included the prostate only, was delineated on the fused CT/MRI scans. The prescription dose was delivered every other day as 5 fractions of 7.5 Gy. Venous blood was obtained before and after SBRT to assess the prostate-specific antigen (PSA) level. Toxicity was evaluated using the CTCAE, v4.03. The median follow-up time was 30.0 months. The median initial PSA level was 7.7 ng/mL. PSA levels decreased in all patients treated with SBRT, and after 5 months, the median PSA was less than 2 ng/mL. The rate of overall 3-yr actuarial biochemical failure free survival was 93.9%. Acute side effects were generally comparable with those of previous studies. The PSA change and toxicity after SBRT for low- to intermediate-risk prostate adenocarcinoma indicates favorable biochemical responses and tolerable levels of toxicity. Additionally short course treatment may produce cost benefit and convenience to patients.
